Abstract:Objectives This study aimed to explore the relationship between plasma proteome and the clinical features of Major Depressive Disorder (MDD) during treatment of acute episode. Methods In this longitudinal observational study, 26 patients hospitalized for moderate to severe MDD were analyzed. The study utilized Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) alongside clinical metrics, including symptomatology derived from the Montgomery-Åsberg Depression Rating Scale (MADRS). Plasma protein analysis was conducted at the onset of acute depression and 6 weeks into treatment. Analytical methods comprised of Linear Models for Microarray Data (LIMMA), Weighted Correlation Network Analysis (WGCNA), Generalized Linear Models, Random Forests, and The Database for Annotation, Visualization and Integrated Discovery (DAVID). Results Five distinct plasma protein modules were identified, correlating with specific biological processes, and uniquely associated with symptom presentation, the disorder’s trajectory, and treatment response. A module rich in proteins related to adaptive immunity was correlated with the manifestation of somatic syndrome, treatment response, and inversely associated with achieving remission. A module associated with cell adhesion was linked to affective symptoms and avolition, and played a role in the initial episodes and treatment response. Another module, characterized by proteins involved in blood coagulation and lipid transport, exhibited negative correlations with a variety of MDD symptoms and was predominantly associated with the manifestation of psychotic symptoms. Conclusion This research points to a complex interplay between the plasma proteome and MDD’s clinical presentation, suggesting that somatic, affective, and psychotic symptoms may represent distinct endophenotypic manifestations of MDD. These insights hold potential for advancing targeted therapeutic strategies and diagnostic tools. Limitations The study’s limited sample size and its naturalistic design, encompassing diverse treatment modalities, present methodological constraints. Furthermore, the analysis focused on peripheral blood proteins, with potential implications for interpretability.

Correlating plasma protein profiles with symptomatology and treatment response in acute phase and early remission of major depressive disorder

An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks

Plasma Disturbance of Phospholipid Metabolism in Major Depressive Disorder by Integration of Proteomics and Metabolomics

Network analysis of plasma proteomes in affective disorders

Identifying Plasma Biomarkers with high specificity for major depressive disorder: A multi-level proteomics study

A Preliminary Investigation on Plasma Cell Adhesion Molecules Levels by Protein Microarray Technology in Major Depressive Disorder

Plasma metabolites were associated with spatial working memory in major depressive disorder

Plasma Proteomics Identifies Proteins and Pathways Associated with Incident Depression in 46,165 Adults

Serum proteomic analysis uncovers novel serum biomarkers for depression

Non-targeted Metabolomics Profiling of Plasma Samples From Patients With Major Depressive Disorder

Common protein networks for various drug regimens of major depression are associated with complement and immunity

Dissection of depression heterogeneity using proteomic clusters

Development of Machine-Learning-driven Signatures for Diagnosing and Monitoring Therapeutic Response in Major Depressive Disorder Using Integrated Immune Cell Profiles and Plasma Cytokines

Quantitative Proteomic Study of the Plasma Reveals Acute Phase Response and LXR/RXR and FXR/RXR Activation in the Chronic Unpredictable Mild Stress Mouse Model of Depression

Peripheral Blood Mononuclear Cell Biomarkers for Major Depressive Disorder: A Transcriptomic Approach

An Analysis of Plasma Reveals Proteins in the Acute Phase Response Pathway to Be Candidate Diagnostic Biomarkers for Depression

Background data for the identification of protein biomarkers in CSF by proteomic approaches

Plasma Metabolomics Profiling of Metabolic Pathways Affected by Major Depressive Disorder

Proteomic analysis of peripheral blood mononuclear cells in first episode psychosis – Protein and peptide-centered approaches to elucidate potential diagnostic biomarkers

Tear fluid biomarkers in major depressive disorder: Potential of spectral methods in biomarker discovery

The relationship between plasma cytokine levels and antidepressant response in patients with first-episode major depressive disorder